{"id":"adalimumab-id","safety":{"commonSideEffects":[{"rate":"10%","effect":"Injection site reaction"},{"rate":"10%","effect":"Headache"},{"rate":"10%","effect":"Fatigue"},{"rate":"5%","effect":"Nausea"},{"rate":"5%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Adalimumab is a fully human monoclonal antibody that binds to tumour necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and subsequent inflammatory response.","oneSentence":"Tumour necrosis factor-alpha inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:49:31.737Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT03607903","phase":"PHASE1, PHASE2","title":"Adalimumab Microneedles in Healthy Volunteers","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-07-11","conditions":"Pain, Injection Site","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Adalimumab ID","genericName":"Adalimumab ID","companyName":"Centre for Human Drug Research, Netherlands","companyId":"centre-for-human-drug-research-netherlands","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adalimumab ID is a microneedle delivery method for the treatment of pain and injection site conditions, compared to subcutaneous injection. Adalimumab ID is a TNF-alpha inhibitor, classified as an antibody inhibitor, targeting tumor necrosis factor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}